Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte S with Dextrose 5% is an intravenous solution providing electrolytes and calories. Dextrose supplies glucose for cellular energy metabolism, while electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure. Acetate and gluconate are metabolized to bicarbonate, providing alkalinizing effect.
ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.
Fluid and electrolyte replacement,Source of calories (dextrose) for parenteral nutrition,Treatment of metabolic acidosis (due to acetate/gluconate content)
Maintenance of fluid and electrolyte balance in patients unable to take oral intake,Correction of metabolic acidosis when bicarbonate is contraindicated or not available,Replacement of electrolytes in hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia
Intravenous infusion; dose determined by fluid and electrolyte requirements. Typical adult maintenance: 100-200 m L/h (2.4-4.8 L/day) depending on clinical status.
Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.
Not applicable for the combination; individual components: dextrose has an elimination half-life of 15-20 minutes, electrolytes are not eliminated as a drug.
Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Dextrose is metabolized via glycolysis and oxidative phosphorylation. Acetate and gluconate are metabolized in the liver and other tissues to bicarbonate.
Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Renal excretion of electrolytes and water; dextrose is metabolized to CO2 and water, with <0.5% excreted unchanged in urine.
Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
Negligible for electrolytes and dextrose (dextrose <5% bound to albumin).
Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
Electrolytes distribute into total body water (0.6 L/kg); dextrose distributes into extracellular fluid (0.2 L/kg).
Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
Intravenous: 100% by definition for all components.
Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
No specific dose adjustment; use with caution in renal impairment due to risk of electrolyte disturbances. Monitor serum potassium and glucose. GFR <30 m L/min: avoid due to potassium content.
Contraindicated in patients with severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia. For GFR 30-50 m L/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 m L/min.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for electrolyte imbalances. Monitor closely.
Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
Intravenous infusion based on weight and clinical need. Typical maintenance: 100 m L/kg/day for first 10 kg, 50 m L/kg/day for 10-20 kg, 20 m L/kg/day for >20 kg. Adjust for dehydration or ongoing losses.
Weight-based dosing: 20-30 m L/kg as a single intravenous infusion, administered at a rate not exceeding 5 m L/kg/hour. Maximum total volume: 1000 m L. Adjust based on clinical status and serum electrolytes.
Use with caution due to increased risk of fluid overload, electrolyte disturbances, and glucose intolerance. Start at lower infusion rates (e.g., 50-100 m L/h) and titrate based on clinical response and renal function.
Elderly patients may require reduced infusion rates (2-5 m L/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.
Not for use in patients with known hypersensitivity to corn or corn products (dextrose derived from corn). Solutions containing aluminum (trace) may be toxic to neonates or patients with renal impairment.
None
Risk of fluid overload, especially in patients with cardiac or renal impairment,Electrolyte imbalances (e.g., hyperkalemia, hypernatremia, hypomagnesemia) should be monitored,Use with caution in patients with severe renal impairment, hepatic failure, or conditions requiring sodium restriction,May cause hyperglycemia in diabetic patients or those with glucose intolerance,Do not administer simultaneously with blood or blood products through same tubing
Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.
Hyperglycemia or uncontrolled diabetes,Hyperkalemia, hypernatremia, or hypermagnesemia,Severe metabolic alkalosis,Known hypersensitivity to any component,Patients with anuria or severe oliguria
Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.
No specific food interactions. However, the dextrose component may affect blood glucose levels; patients on diabetic diets should monitor carbohydrate intake. Avoid excessive alcohol consumption due to risk of hypoglycemia or electrolyte imbalance.
No direct food interactions; however, patients should avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia is a concern. Monitor dietary sodium and fluid intake as per clinical status.
No teratogenic risk associated. Dextrose 5% and balanced electrolyte solution (Isolyte S) are not known to cause fetal harm. Use during pregnancy does not increase risk of congenital anomalies.
ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.
Compatible with breastfeeding. Dextrose and electrolytes are normal constituents of breast milk. M/P ratio is not applicable as these are endogenous substances.
ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
No specific dose adjustment required for pregnancy. Monitor for fluid overload and electrolyte imbalances due to increased plasma volume and GFR.
No dose adjustment is required for pregnancy. However, pregnant patients may have increased plasma volume and altered renal function; infusion rates should be individualized based on clinical status and serum electrolyte monitoring. Rapid correction of electrolyte imbalances should be avoided to prevent fetal osmotic shifts.
ISOLYTE S with Dextrose 5% is an isotonic crystalloid solution containing electrolytes and dextrose. It should not be used for resuscitation in hemorrhagic shock as it may cause hyperglycemia and osmotic diuresis. Monitor serum glucose closely in diabetic patients. Do not administer simultaneously with blood products through the same tubing due to risk of hemolysis. Discard any unused portion; do not store partially used bags.
ISOLYTE E is a balanced electrolyte solution with 5% dextrose, used for maintenance fluid therapy. Monitor serum potassium closely in renal impairment; contains 20 m Eq/L potassium. Caution in patients with hyperkalemia, renal failure, or metabolic alkalosis. Do not administer simultaneously with blood products due to risk of hemolysis. Observe for signs of fluid overload in patients with heart failure.
This solution is given through a vein to replace fluids and electrolytes.,Tell your doctor if you have diabetes, kidney problems, or heart failure.,You may need blood tests to monitor your sugar and electrolyte levels.,Report any swelling, shortness of breath, or pain at the IV site.
This solution is used to replace fluids and electrolytes and provide calories. Tell your doctor if you have kidney problems, heart disease, or are on a low-potassium diet. Report any swelling, shortness of breath, or irregular heartbeat. Do not take over-the-counter potassium supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte S with Dextrose 5% is an intravenous solution providing electrolytes and calories. Dextrose supplies glucose for cellular energy metabolism, while electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure. Acetate and gluconate are metabolized to bicarbonate, providing alkalinizing effect.. ISOLYTE E IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by fluid and electrolyte requirements. Typical adult maintenance: 100-200 m L/h (2.4-4.8 L/day) depending on clinical status.. The standard adult dose of ISOLYTE E IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No teratogenic risk associated. Dextrose 5% and balanced electrolyte solution (Isolyte S) are not known to cause fetal harm. Use during pregnancy does not increase risk of congenit. ISOLYTE E IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.